Key facts
Explore key financial and product revenue facts about Bristol Myers Squibb.
- X
ELIQUIS® (apixaban), $12.2 billion
OPDIVO®(nivolumab), $9 billion
REVLIMID® (lenalidomide), $6.1 billion
ORENCIA® (abatacept), $3.6 billion
POMALYST® / Imnovid® (pomalidomide), $3.4 billion
YERVOY® (ipilimumab), $2.2 billion
SPRYCEL® (dasatinib), $1.9 billion
REBLOZYL® (luspatercept-aamt), $1.0 billion
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $1.0 billion
OPDUALAG™(nivolumab and relatlimab-rmbw): $627 million
ABECMA® (idecabtagene vicleucel), $472 million
ZEPOSIA® (ozanimod), $434 million
BREYANZI® (lisocabtagene maraleucel), $364 million
CAMZYOS® (mavacamten), $231 million
SOTYKTU™(deucravacitinib), $170 million
ONUREG® (azacitidine tablets), $168 million
INREBIC® (fedratinib), $110 million
AUGTYRO™ (repotrectinib), $1 million
Mature and other products* $1.9 billion
*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.
Please click on the product links to see the Full Prescribing Information for ABECMA®, ABRAXANE®, AUGTYRO™, BREYANZI®, CAMZYOS® ELIQUIS®, INREBIC®, ONUREG®, OPDIVO®, OPDUALAG™, ORENCIA®, POMALYST® , REBLOZYL®, REVLIMID® , SOTYKTU™ , SPRYCEL® , YERVOY® and ZEPOSIA® including Boxed WARNINGS for ABECMA®, ABRAXANE®, BREYANZI®, CAMZYOS®, ELIQUIS®, INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Updated October 2024